Association Between C-reactive Protein and Risk of Cancer: A Meta-analysis of Prospective Cohort Studies |
Guo, Yong-Zhong
(Department of Respiratory Medicine, Xuzhou Central Hospital, Affiliated Xuzhou Hospital of Medical College of Southeast University)
Pan, Lei (Guangzhou Institute of Respiratory Diseases, State Key Lab of Respiratory Diseases, The First Affiliated Hospital of Guangzhou Medical College) Du, Chang-Jun (Department of Respiratory Medicine, Xuzhou Central Hospital, Affiliated Xuzhou Hospital of Medical College of Southeast University) Ren, Dun-Qiang (Department of Respiratory Medicine, The Affiliated Hospital of Medical College Qingdao University) Xie, Xiao-Mei (Department of Radiotherapy, Xuzhou Central Hospital, Affiliated Xuzhou Hospital of Medical College of Southeast University) |
1 | Van Hemelrijck M, Holmberg L, Garmo H, et al (2011). Association between levels of C-reactive protein and leukocytes and cancer: three repeated measurements in the Swedish AMORIS study. Cancer Epidemiol Biomarkers Prev, 20, 428-37. DOI ScienceOn |
2 | Zhang SM, Buring JE, Lee IM, Cook NR, Ridker PM (2005). C-reactive protein levels are not associated with increased risk for colorectal cancer in women. Ann Intern Med, 142, 425-32. DOI ScienceOn |
3 | Zhang SM, Lin J, Cook NR, et al (2007). C-reactive protein and risk of breast cancer. J Natl Cancer Inst, 99, 890-4. DOI ScienceOn |
4 | Lubin JH, Alavanja MC, Caporaso N, et al (2007). Cigarette smoking and cancer risk: modeling total exposure and intensity. Am J Epidemiol, 166, 479-89. DOI ScienceOn |
5 | Mantovani A, Allavena P, Sica A, Balkwill F (2008). Cancer-related inflammation. Nature, 454, 436-44. DOI ScienceOn |
6 | Moore MM, Chua W, Charles KA, Clarke SJ (2010). Inflammation and cancer: causes and consequences. Clin Pharmacol Ther, 87, 504-8. DOI ScienceOn |
7 | Orsini N, Bellocco R, Greenland S (2006). Generalized least squares for trend estimation of summarized dose-response data. Stata J, 6, 40-57. |
8 | Otani T, Iwasaki M, Sasazuki S, Inoue M, Tsugane S (2006). Plasma C-reactive protein and risk of colorectal cancer in a nested casecontrol study: Japan Public Health Center-based prospective study. Cancer Epidemiol Biomarkers Prev, 15, 690-5. DOI ScienceOn |
9 | Pearson TA, Mensah GA, Alexander RW, et al (2003). Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation, 107, 499-511. DOI ScienceOn |
10 | Pierce BL, Biggs ML, DeCambre M, et al (2009). C-reactive protein, interleukin-6, and prostate cancer risk in men aged 65 years and older. Cancer Causes Control, 20, 1193-203. DOI ScienceOn |
11 | Pine SR, Mechanic LE, Enewold L, et al (2011). Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J Natl Cancer Inst, 103, 1112-22. DOI ScienceOn |
12 | Platz EA, De Marzo AM, Erlinger TP, et al (2004). No association between pre-diagnostic plasma C-reactive protein concentration and subsequent prostate cancer. Prostate, 59, 393-400. DOI ScienceOn |
13 | Prizment AE, Anderson KE, Visvanathan K, Folsom AR (2011). Association of inflammatory markers with colorectal cancer incidence in the atherosclerosis risk in communities study. Cancer Epidemiol Biomarkers Prev, 20, 297-307. DOI ScienceOn |
14 | Proctor MJ, Talwar D, Balmar SM, et al (2010). The relationship between the presence and site of cancer, an inflammation-based prognostic score and biochemical parameters. Initial results of the Glasgow Inflammation Outcome Study. Br J Cancer, 103, 870-6. DOI ScienceOn |
15 | Sgambato A, Cittadini A (2010). Inflammation and cancer: a multifaceted link. Eur Rev Med Pharmacol Sci, 14, 263-8. |
16 | Ben-Baruch A (2003). Host microenvironment in breast cancer development: inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor-microenvironment interactions. Breast Cancer Res, 5, 31-6. DOI |
17 | Siemes C, Visser LE, Coebergh JW, et al (2006). C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J Clin Oncol, 24, 5216-22. DOI ScienceOn |
18 | Trichopoulos D, Psaltopoulou T, Orfanos P, Trichopoulou A, Boffetta P (2006). Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol Biomarkers Prev, 15, 381-4. DOI ScienceOn |
19 | Tsilidis KK, Branchini C, Guallar E, et al (2008). C-reactive protein and colorectal cancer risk: a systematic review of prospective studies. Int J Cancer, 123, 1133-40. DOI ScienceOn |
20 | Bianchini F, Kaaks R, Vainio H (2002). Overweight, obesity, and cancer risk. Lancet Oncol, 3, 565-74. DOI ScienceOn |
21 | Bochud M, Rousson V (2010). Usefulness of Mendelian randomization in observational epidemiology. Int J Environ Res Public Health, 7, 711-28. DOI ScienceOn |
22 | Chaturvedi AK, Caporaso NE, Katki HA, et al (2010). C-reactive protein and risk of lung cancer. J Clin Oncol, 28, 2719-26. DOI ScienceOn |
23 | Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A (2009). Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis, 30, 1073-81. DOI ScienceOn |
24 | Dos SSI, De Stavola BL, Pizzi C, Meade TW (2010). Circulating levels of coagulation and inflammation markers and cancer risks: individual participant analysis of data from three long-term cohorts. Int J Epidemiol, 39, 699-709. DOI ScienceOn |
25 | Gur T, Demir H, Kotan MC (2011). Tumor markers and biochemical parameters in colon cancer patients before and after chemotherapy. Asian Pac J Cancer Prev, 12, 3147-50. |
26 | Duval S, Tweedie R (2000). Trim and fill: A simple funnel-plotbased method of testing and adjusting for publication bias in meta-analysis. Biometrics, 56, 455-63. DOI ScienceOn |
27 | Greenland S, Longnecker MP (1992). Methods for trend estimation from summarized dose-response data, with applications to metaanalysis. Am J Epidemiol, 135, 1301-9. |
28 | Gunter MJ, Stolzenberg-Solomon R, Cross AJ, et al (2006). A prospective study of serum C-reactive protein and colorectal cancer risk in men. Cancer Res, 66, 2483-7. DOI ScienceOn |
29 | Haverkamp J, Charbonneau B, Ratliff TL (2008). Prostate inflammation and its potential impact on prostate cancer: a current review. J Cell Biochem, 103, 1344-53. DOI ScienceOn |
30 | Heikkila K, Harris R, Lowe G, et al (2009). Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control, 20, 15-26. DOI ScienceOn |
31 | Heikkila K, Silander K, Salomaa V, et al (2011). C-reactive proteinassociated genetic variants and cancer risk: findings from FINRISK 1992, FINRISK 1997 and Health 2000 studies. Eur J Cancer, 47, 404-12. DOI ScienceOn |
32 | Helzlsouer KJ, Erlinger TP, Platz EA (2006). C-reactive protein levels and subsequent cancer outcomes: results from a prospective cohort study. Eur J Cancer, 42, 704-7. DOI ScienceOn |
33 | Higgins JPT, Sally Green P (2011). Cochrane handbook for systematic reviews of interventions. New York: John Wiley & Sons. |
34 | Allin KH, Bojesen SE, Nordestgaard BG (2009). Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol, 27, 2217-24. DOI ScienceOn |
35 | Il'Yasova D, Colbert LH, Harris TB, et al (2005). Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev, 14, 2413-8. DOI ScienceOn |
36 | Lee S, Choe JW, Kim HK, Sung J (2011). High-sensitivity C-reactive protein and cancer. J Epidemiol, 21, 161-8. DOI |
37 | Aleksandrova K, Jenab M, Boeing H, et al (2010). Circulating C-reactive protein concentrations and risks of colon and rectal cancer: a nested case-control study within the European Prospective Investigation into Cancer and Nutrition. Am J Epidemiol, 172, 407-18. DOI ScienceOn |
38 | Allin KH, Nordestgaard BG, Zacho J, Tybjaerg-Hansen A, Bojesen SE (2010). C-reactive protein and the risk of cancer: a mendelian randomization study. J Natl Cancer Inst, 102, 202-6. DOI ScienceOn |
39 | Allin KH, Bojesen SE, Johansen JS, Nordestgaard BG (2012). Cancer risk by combined levels of YKL-40 and C-reactive protein in the general population. Br J Cancer, 106, 199-205. DOI ScienceOn |
40 | Austin PC, Anderson GM, Cigsar C, Gruneir A (2012). Comparing the cohort design and the nested case-control design in the presence of both time-invariant and time-dependent treatment and competing risks: bias and precision. Pharmacoepidemiol Drug Saf, 21, 714-24. DOI ScienceOn |
41 | Babu SN, Chetal G, Kumar S (2012). Macrophage migration inhibitory factor: a potential marker for cancer diagnosis and therapy. Asian Pac J Cancer Prev, 13, 1737-44. DOI ScienceOn |
42 | Balkwill F, Mantovani A (2001). Inflammation and cancer: back to Virchow? Lancet, 357, 539-45. DOI ScienceOn |
![]() |